Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HMUIRB2402 | Other Identifier | Hanoi Medical University Institutional Review Board | |
| 05/CN-BVĐKHN | Other Identifier | Ethics Committee in Biomedical Research, Hanoi Department of Health |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to compare the outcomes of two ovarian stimulation protocols used in in vitro fertilization (IVF): the progestin-primed ovarian stimulation (PPOS) protocol and the GnRH antagonist protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PPOS Protocol | Experimental | Participants receive ovarian stimulation using the progestin-primed ovarian stimulation (PPOS) protocol for in vitro fertilization. |
|
| GnRH Antagonist Protocol | Active Comparator | Participants receive ovarian stimulation using a GnRH antagonist protocol for in vitro fertilization. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Progestin-Primed Ovarian Stimulation (PPOS) | Drug | Ovarian stimulation using a progestin-primed ovarian stimulation (PPOS) protocol, including gonadotropins combined with oral progestin for pituitary suppression during in vitro fertilization treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Ongoing pregnancy rate at 12 weeks | Ongoing pregnancy defined as a viable intrauterine pregnancy with fetal cardiac activity confirmed by ultrasound at or beyond 12 weeks of gestation. | Up to 12 weeks after embryo transfer |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Oocytes Retrieved | Total number of oocytes retrieved per ovarian stimulation cycle at the time of oocyte retrieval | From ovarian stimulation start to oocyte retrieval (approximately 10-14 days) |
| Number of Mature (MII) Oocytes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Female participants with polycystic ovary syndrome (PCOS) who are indicated for IVF treatment are eligible for this study
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Phuong Duy Nguyen, MD, MS | Contact | +84 986656835 | nguyenduyphuongncs44@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Phuong Duy Nguyen, MD, MS | Hanoi General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hanoi General Hospital | Recruiting | Hanoi | Hanoi | 10000 | Vietnam |
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| D007247 | Infertility, Female |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| GnRH Antagonist Protocol | Drug | Ovarian stimulation using a gonadotropin-releasing hormone (GnRH) antagonist protocol for pituitary suppression during in vitro fertilization treatment. |
|
Number of mature oocytes at the metaphase II (MII) stage identified at the time of oocyte retrieval
| At the time of oocyte retrieval (approximately 10-14 days after stimulation start) |
| Live birth rate | Live birth rate of live-born infants at ≥24 weeks of gestation or with birth weight ≥500 g and signs of life after birth. | Up to delivery (approximately 9-12 months after embryo transfer) |
| Clinical pregnancy rate | Clinical pregnancy defined as the presence of a gestational sac with fetal cardiac activity confirmed by ultrasound | 6-7 weeks after embryo transfer |
| Fertilization Rate | Fertilization rate, defined as the percentage of fertilized oocytes | 16-18 hours after oocyte insemination |
| Number of Usable Embryos | From fertilization to embryo assessment (approximately Day 3 to Day 5 after oocyte retrieval). |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D007246 | Infertility |